AUTHORS
Natalie Frances Berger, MD, Rosa Bin Choi, MD2, Olivia Katz, MD3, Nada Fadl, DO4, Ishaan Jindal5, Christina Cappola6, Jackson Hans Bauer7, Philip Zoltick, MD8, Karlla Brigatti, MS9, Hooda Said, MS10, Marco D Carpenter, PhD11, Mohamad-Gabriel Alameh, PhD12, Giulia Pavani, PhD13, William Peranteau, MD14
AFFILIATIONS
1 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
2 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
3 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
4 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
5 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
6 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
7 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
8 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
9 Clinic for Special Children, Gordonville, Pennsylvania, United States
10 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
11 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
12 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
13 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
14 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
ABSTRACT
Introduction
Pyruvate kinase deficiency (PKD) is a rare recessive genetic disease of red blood cells that results in a chronic hemolytic anemia. It is caused by pathogenic variants in the PKLR gene resulting in a deficiency of erythroid pyruvate kinase, which converts phosphoenolpyruvate to pyruvate in glycolysis and produces 50% of the ATP in red blood cells. There is no cure for PKD, and current treatments are largely supportive. In select cases the anemia can result in nonimmune fetal hydrops and can be lethal prenatally without fetal blood transfusions. The c.1436G>A missense mutation is a recurrent variant that results in a severe disease phenotype and is potentially amenable to correction via adenine base editing. In the current study we screen adenine base editor (ABE) and guide RNA (gRNA) combinations in HEK293 cells engineered to express the recurrent human variant and identify an ABE/gRNA combination with high on-target activity. Furthermore, we develop and characterize a humanized mouse model containing the PKLR c.1436G>A variant. Finally, with an eye toward future studies to correct the variant and phenotype in the mouse model, we assess in vivo LNP mediated mRNA delivery to hematopoietic stem cells (HSCs) in fetal mouse recipients, hypothesizing that the liver location of HSCs during fetal development allows for efficient LNP-mediated targeting as LNPs naturally home to the liver.
Methods
HEK293 cells were transduced with a lentivirus containing the PKLR c.1436G>A variant and unique DNA sequences to distinguish the lentiviral insert from the endogenous DNA sequence. ABE/gRNA combinations were screened in the PKLR c.1436G>A HEK293 cells and assessed by next generation sequencing (NGS) for on-target editing to correct the variant. A humanized PKLR c.1436G>A mouse model was generated using homology directed repair to insert the c.1436G>A variant and surrounding human DNA sequence in the endogenous mouse pklr locus. PKLR c.1436G>A mice were characterized with monthly complete blood counts (CBC) to assess hematologic parameters.
Finally, a fluorescent reporter mouse model was used to address the hypothesis that LNP-mediated mRNA delivery to HSCs is more efficient in fetal compared to adult recipients. Specifically, CAG-Sun1/sfGFP (Sun1GFP) mice with floxed nuclear-localized green fluorescent protein (GFP) were injected with an LNP carrying Cre recombinase mRNA (LNP.Cre), which drives nuclear GFP expression in successfully transduced cells. Mice received 0.75 mg/kg IV injections at gestational day 14 (E14) via the vitelline vein (n=3), or at 6 weeks of age via the retroorbital sinus (n=2). Bone marrow was harvested at 11-13 weeks of age. Flow cytometry was used to assess GFP expression in LSK (Lin-Sca-1+c-Kit+), HSPC (Lin-Sca-1+c-Kit+Flt3-), and LT-HSC (Lin-Sca-1+c-Kit+Flt3-CD48-CD150+) cells. Cell analyses were performed on a Cytek Aurora flow cytometer, and the acquired data were analyzed using BD FlowJo software.
Results
A total of 11 ABE/gRNA combinations were screened in PKLR c.1436G>A HEK293 cells. ABE8.8 and gRNA6 resulted in the highest on-target editing (average 26% in triplicate studies, target adenine at position 6). Synonymous bystander editing without on target correction occurred at a rate of 0.17% and no significant non-synonymous bystander editing was observed.
PKLR c.1436G>A mice were bred to homozygosity and were viable and fertile. Homozygous PKLR c.1436G>A mice demonstrated a mild disease phenotype with significantly lower hemoglobin (13.7 vs. 15.33; p<0.01) and erythrocytes (9.3 vs. 10.3; p<0.01), and higher reticulocyte percent (4.4 vs. 3.2; p<0.01) at 3 months of age compared to control C57BL/6 mice.
Finally, GFP expression was significantly higher in bone marrow LSK cells from fetal recipients of LNP.Cre compared to adult recipients (51.7% vs. 33%; p<0.05). There was also a trend toward greater GFP expression in HSPC cells and LT-HSCs in the E14 group compared to the adult group, however, it was not statistically significant (54.8% vs. 38.4%; p=0.07, 54.4% vs. 43.8%; p=0.26, respectively).
Conclusions
An efficient adenine base editing strategy to correct a recurrent disease-causing variant of PKD exists as does a nonviral LNP approach to deliver mRNA to HSCs. Studies are underway to assess the ability of in vivo prenatal and postnatal adenine base editing via systemic LNP delivery to correct the PKLR c.1436G>A variant and mild disease phenotype in the humanized mouse model.
DISCLOSURES
Natalie Frances Berger, MD: No relevant conflicts of interest to declare.